These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37780073)

  • 1. Allergic reactions to the Ad26.COV2.S vaccine in South Africa.
    Peter J; Day C; Takuva S; Takalani A; Engelbrecht I; Garrett N; Goga A; Louw V; Opie J; Jacobson B; Sanne I; Gail-Bekker L; Gray G
    J Allergy Clin Immunol Glob; 2022 Feb; 1(1):2-8. PubMed ID: 37780073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
    Bekker LG; Garrett N; Goga A; Fairall L; Reddy T; Yende-Zuma N; Kassanjee R; Collie S; Sanne I; Boulle A; Seocharan I; Engelbrecht I; Davies MA; Champion J; Chen T; Bennett S; Mametja S; Semenya M; Moultrie H; de Oliveira T; Lessells RJ; Cohen C; Jassat W; Groome M; Von Gottberg A; Le Roux E; Khuto K; Barouch D; Mahomed H; Wolmarans M; Rousseau P; Bradshaw D; Mulder M; Opie J; Louw V; Jacobson B; Rowji P; Peter JG; Takalani A; Odhiambo J; Mayat F; Takuva S; Corey L; Gray GE; ;
    Lancet; 2022 Mar; 399(10330):1141-1153. PubMed ID: 35305740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study).
    Jacobson BF; Schapkaitz E; Takalani A; Rowji PF; Louw V; Opie J; Bekker LG; Garrett N; Goga A; Reddy T; Zuma NY; Sanne I; Seocharan I; Peter J; Robinson M; Collie S; Khan A; Takuva S; Gray G
    BMJ Med; 2023; 2(1):e000302. PubMed ID: 37063238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS.
    Yan MM; Zhao H; Li ZR; Chow JW; Zhang Q; Qi YP; Wu SS; Zhong MK; Qiu XY
    Front Pharmacol; 2022; 13():921760. PubMed ID: 36419624
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
    Takalani A; Robinson M; Jonas P; Bodenstein A; Sambo V; Jacobson B; Louw V; Opie J; Peter J; Rowji P; Seocharan I; Reddy T; Yende-Zuma N; Khutho K; Sanne I; Bekker LG; Gray G; Garrett N; Goga A;
    Vaccine; 2024 Feb; 42(6):1195-1199. PubMed ID: 38278629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
    Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
    JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    Takuva S; Takalani A; Seocharan I; Yende-Zuma N; Reddy T; Engelbrecht I; Faesen M; Khuto K; Whyte C; Bailey V; Trivella V; Peter J; Opie J; Louw V; Rowji P; Jacobson B; Groenewald P; Dorrington RE; Laubscher R; Bradshaw D; Moultrie H; Fairall L; Sanne I; Gail-Bekker L; Gray G; Goga A; Garrett N;
    PLoS Med; 2022 Jun; 19(6):e1004024. PubMed ID: 35727802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022.
    Woo EJ; Gee J; Marquez P; Baggs J; Abara WE; McNeil MM; Dimova RB; Su JR
    Vaccine; 2023 Jul; 41(30):4422-4430. PubMed ID: 37321898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
    Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW
    Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021.
    Woo EJ; Mba-Jonas A; Dimova RB; Alimchandani M; Zinderman CE; Nair N
    JAMA; 2021 Oct; 326(16):1606-1613. PubMed ID: 34617967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
    Sadoff J; Gray G; Vandebosch A; Cárdenas V; Shukarev G; Grinsztejn B; Goepfert PA; Truyers C; Fennema H; Spiessens B; Offergeld K; Scheper G; Taylor KL; Robb ML; Treanor J; Barouch DH; Stoddard J; Ryser MF; Marovich MA; Neuzil KM; Corey L; Cauwenberghs N; Tanner T; Hardt K; Ruiz-Guiñazú J; Le Gars M; Schuitemaker H; Van Hoof J; Struyf F; Douoguih M;
    N Engl J Med; 2021 Jun; 384(23):2187-2201. PubMed ID: 33882225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Second Allergic Reaction to SARS-CoV-2 Vaccines: A Systematic Review and Meta-analysis.
    Chu DK; Abrams EM; Golden DBK; Blumenthal KG; Wolfson AR; Stone CA; Krantz MS; Shaker M; Greenhawt M
    JAMA Intern Med; 2022 Apr; 182(4):376-385. PubMed ID: 35188528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylaxis is rare due to CoronaVac in a population of healthcare workers.
    Öztürk BÖ; Akdemir İ; Azap A; Çelik G; Bavbek S; Mungan D
    Asia Pac Allergy; 2022 Oct; 12(4):e35. PubMed ID: 36452009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021.
    See I; Su JR; Lale A; Woo EJ; Guh AY; Shimabukuro TT; Streiff MB; Rao AK; Wheeler AP; Beavers SF; Durbin AP; Edwards K; Miller E; Harrington TA; Mba-Jonas A; Nair N; Nguyen DT; Talaat KR; Urrutia VC; Walker SC; Creech CB; Clark TA; DeStefano F; Broder KR
    JAMA; 2021 Jun; 325(24):2448-2456. PubMed ID: 33929487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.
    Pareek M; Sessa P; Polverino P; Sessa F; Kragholm KH; Sessa M
    Front Cardiovasc Med; 2023; 10():1210007. PubMed ID: 38075965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(4):125-129. PubMed ID: 33507892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination-United States, December 2020 to August 2021.
    See I; Lale A; Marquez P; Streiff MB; Wheeler AP; Tepper NK; Woo EJ; Broder KR; Edwards KM; Gallego R; Geller AI; Jackson KA; Sharma S; Talaat KR; Walter EB; Akpan IJ; Ortel TL; Urrutia VC; Walker SC; Yui JC; Shimabukuro TT; Mba-Jonas A; Su JR; Shay DK
    Ann Intern Med; 2022 Apr; 175(4):513-522. PubMed ID: 35038274
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.